Diligence memo · auto-generated · as of July 2, 2026
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Goldfinch Bio, Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Goldfinch Bio, Inc. has raised $70M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $70M on 2020-06-29.
Most recent recorded round closed around 2020-06-29.
Valuation (modeled)modeled
Provath models Goldfinch Bio, Inc. at approximately $2.4B (range $226M–$6.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.48× the median modeled value of Series C Pharmaceuticals companies in 2019–2021 (33 peers) — value vs value, same stage and era. Within the normal band (148% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 6.0 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 86% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Verastem, Inc., Sentia Wellness, Inc., Oyster Point Pharma, Inc., Terns Pharmaceuticals, Inc., Theseus Pharmaceuticals, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.